# US 2021/0332115 A1 · Humanized anti-complement factor bb antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332115 A1
- Document ID: US20210332115A1
- Status: Published application
- Kind: A1
- Application number: 17/234,618
- Filed: 2021-04-19
- Published: 2021-10-28
- Earliest claimed: 2020-04-20
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Graham Parry; Stephen Moore; Michael Storek; Nina C. Leksa
- Web page: https://patentgrep.com/patent/US20210332115A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.

## Claims

### Claim 1

A humanized antibody that binds specifically to human complement factor Bb protein, wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 27.

### Claim 2 (depends on 1, 2)

The humanized antibody of claim 1, wherein the humanized antibody is a multispecific antibody. The humanized antibody of claim 2, wherein the multispecific antibody is a bispecific antibody.

### Claim 4 (depends on 1)

The humanized antibody of claim 1, wherein the humanized antibody is selected from the group consisting of an Ig monomer, a Fab fragment, a F(ab′)2 fragment, a scFv, a scAb, and a Fv.

### Claim 5 (depends on 1)

The humanized antibody of claim 1, wherein the humanized antibody comprises a heavy chain constant region of the isotype IgG1, IgG2, IgG3, or IgG4.

### Claim 6 (depends on 5)

The humanized antibody of claim 5, wherein the humanized antibody comprises an IgG4 constant region.

### Claim 7 (depends on 6)

The humanized antibody of claim 6, wherein the IgG4 constant region comprises an S241P substitution and an L248E substitution, by Kabat numbering.

### Claim 8 (depends on 7)

The humanized antibody of claim 7, wherein the IgG4 constant region further comprises an M459L substitution and an N466S substitution, by Kabat numbering.

### Claim 9 (depends on 1)

The humanized antibody of claim 1, wherein the humanized antibody comprises a heavy chain constant region comprising the amino acid sequence of any one of SEQ ID Nos. 28-30.

### Claim 10 (depends on 1)

The humanized antibody of claim 1, wherein the humanized antibody comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO: 31.

### Claim 11 (depends on 9)

The humanized antibody of claim 9, wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 32 and a light chain comprising the amino acid sequence of SEQ ID NO: 35.

### Claim 12 (depends on 9)

The humanized antibody of claim 9, wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 33 and a light chain comprising the amino acid sequence of SEQ ID NO: 35.

### Claim 13 (depends on 9)

The humanized antibody of claim 9, wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 34 and a light chain comprising the amino acid sequence of SEQ ID NO: 35.

### Claim 14 (depends on 1)

A conjugate comprising the humanized antibody of claim 1.

### Claim 15 (depends on 14)

The conjugate of claim 14, wherein the humanized antibody is conjugated to a therapeutic agent.

### Claim 16 (depends on 1)

A composition comprising the humanized antibody of claim 1.

### Claim 17 (depends on 16)

The composition of claim 16, further comprising a pharmaceutically acceptable excipient.

### Claim 18 (depends on 1)

A device comprising the humanized antibody of claim 1.

### Claim 19 (depends on 1)

A nucleic acid or nucleic acid set encoding or collectively encoding the humanized antibody of claim 1.

### Claim 20 (depends on 19)

A vector or vector set comprising the nucleic acid or nucleic acid set of claim 19.

### Claim 21 (depends on 19)

An isolated cell comprising the nucleic acid or nucleic acid set of claim 19.

### Claim 22 (depends on 21)

The isolated cell of claim 21, wherein the cell is a mammalian cell.

### Claim 23 (depends on 22)

The isolated cell of claim 22, wherein the mammalian cell is selected from human embryonic kidney (HEK) cells, Chinese hamster ovary (CHO) cells, NSO myeloma cells, SP2 cells, COS cells, and mammary epithelial cells.

### Claim 24 (depends on 21)

A method of producing a humanized antibody that binds specifically to human complement factor Bb protein, wherein the method comprises culturing the isolated cell of claim 21 to produce the humanized antibody.

### Claim 25

A method of treating a subject having a complement-mediated disease or disorder, wherein the method comprises administering to the subject a therapeutically effective amount of a humanized antibody that binds specifically to human complement factor Bb protein, wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 27.

### Claim 26 (depends on 25)

The method of claim 25, wherein the complement-mediated disease or disorder is PNH, aHUS, IgA nephropathy, lupus nephritis, ANCA vasculitis, membranous nephropathy, or C3 glomerulonephritis (C3GN).

### Claim 27

A method of inhibiting a complement pathway activity in a subject, wherein the method comprises administering to the subject a humanized antibody that binds specifically to human complement factor Bb protein, wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 27.

### Claim 28

A humanized antibody that binds specifically to human complement factor Bb protein and comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 17 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 26.

### Claim 29 (depends on 28)

A method of treating a subject having a complement-mediated disease or disorder, wherein the method comprises administering to the subject a therapeutically effective amount of the humanized antibody of claim 28.

### Claim 30 (depends on 28)

A method of inhibiting a complement pathway activity in a subject, wherein the method comprises administering to the subject the humanized antibody of claim 28.
